Malignant hyperpyrexia.
Malignant hyperpyrexia is a genetically related syndrome that cannot be predicted reliably in advance of administration of anesthesia except by a strong family history. The definitive etiology is unknown, although triggering agents that release calcium from the calcium-storing sarcoplasmic membrane of the muscle cell are highly suspect. As soon as the syndrome is diagnosed, therapy must be prompt, vigorous, and carried out with the same urgency as a cardiac arrest. Specific therapy with dantrolene sodium may prove to be an answer to this serious problem in anesthetic practice.
D058186:Acute Kidney Injury; D000255:Adenosine Triphosphate / Q000378:metabolism; D000777:Anesthetics; D001639:Bicarbonates / Q000627:therapeutic use; D001831:Body Temperature; D002118:Calcium / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D009119:Muscle Contraction; D011342:Procainamide / Q000627:therapeutic use; D011343:Procaine / Q000627:therapeutic use; D012519:Sarcoplasmic Reticulum / Q000378:metabolism
D000777:Anesthetics; D001639:Bicarbonates; D011343:Procaine; D000255:Adenosine Triphosphate; D003402:Creatine Kinase; D011342:Procainamide; D002118:Calcium